logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line

< Back

Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line

Drugs

Cancer and Palliative Care

September 2019


Atezolizumab as an intravenous infusion in combination with an intravenous infusion of paclitaxel (chemotherapy) is in clinical development for the first-line treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). TNBC is a type of breast cancer in which the cancer cells do not express receptors for oestrogen or progesterone or HER2 protein. Treatment of TNBC is challenging because of a lack of targeted therapy, aggressive disease course, and relatively poor prognosis. Treatment is usually through a combination of surgery, radiotherapy, and chemotherapy.
Atezolizumab is a cancer medicine that enhances T-cell (part of the immune system) activity against tumours. Paclitaxel is a chemotherapy that inhibits cell growth by preventing cell division. The combination may offer an additional first-line treatment option to improve clinical effectiveness in the treatment of people with inoperable, locally advanced or metastatic TNBC, an aggressive disease with no approved targeted therapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts